Phase II Trial of Cisplatin Plus Prednisone in Docetaxel-Refractory Castration-Resistant Prostate Cancer Patients

Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-011-1594-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase II Randomized Study of Figitumumab Plus Docetaxel and Docetaxel Alone With Crossover for Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

Salvage Therapy for Castration-Refractory Prostate Cancer Resistant to Docetaxel

Japanese Journal of Urology
Urology
2013English

Phase II, Multicenter, Randomized Trial of Docetaxel Plus Prednisone With or Without Cediranib in Men With Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Phase II Pilot Study of the Prednisone to Dexamethasone Switch in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients With Limited Progression on Abiraterone Plus Prednisone (SWITCH Study)

British Journal of Cancer
Cancer ResearchOncology
2018English

Phase I Trial With a Combination of Docetaxel and 153Sm-Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2011English

Docetaxel Rechallenge in Patients With Castration-Resistant Prostate Cancer — A Review

European Oncology and Haematology
OncologyHematology
2012English

A Phase II Trial of Prostate-Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Taxane-Refractory Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) With Docetaxel in Metastatic Castration‐Resistant Prostate Cancer (mCRPC)

Oncologist
Cancer ResearchMedicineOncology
2019English

Guideline Adherence in Docetaxel Treatment of Castration Resistant Prostate Cancer (CRPC) Patients in a Real-World Population: The Castration Resistant Prostate Cancer Registry (CAPRI) in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy